Swiss pharmaceutical giant Novartis has pledged to invest $23 billion in U.S. manufacturing and research facilities over the next five years. This significant commitment comes as the company aims to expand its operations in the United States while navigating the challenges posed by renewed tariff threats from the Trump administration. Alongside building a $1.1 billion research hub in San Diego, Novartis follows other major pharma companies in announcing multibillion-dollar investments to bolster their U.S. presence. The move is seen as a response to the current tariff climate, reflecting the pressures faced by the pharmaceutical sector.